


Cite this: *RSC Adv.*, 2025, 15, 26173

LC-MS/MS-guided separation of guaiacolane-type sesquiterpenes with anti-inflammatory activities from *Chrysanthemum indicum*†

Xinyue Li,^a Yanfen Cai,^a Yunshuang Hu,^a Limei Miu,^a Yanyu Zhang,^d Shiyun Huang,^a Min Wei,^e Qing Ma,^e Zhongqiu Liu,^{ab} Hua Zhou^{*bc} and Peng Wu^{†ab}

Four previously undescribed compounds, including three guaiacane-type sesquiterpenoids (1–3) and one oleanane-type triterpenoid (4), along with seven known sesquiterpenoids, were isolated from the aerial parts of *Chrysanthemum indicum* using LC-MS/MS-guided fractionation. Structures were elucidated by IR, UV, HR-ESI-MS, and 1D/2D NMR analyses, and their absolute configurations were determined by ECD calculations. The anti-inflammatory activity was evaluated in LPS-stimulated RAW264.7 cells with NF- κ B translocation by high-content imaging (HCI). Compound 2 reduced NF- κ B translocation (IC₅₀ = 9.70 μ M) without cytotoxicity at 20 μ M. Compounds 8 and 9 showed potent activity (IC₅₀ = 2.04 and 1.21 μ M, respectively) and no cytotoxicity at 6.25 μ M.

Received 22nd May 2025
Accepted 15th July 2025

DOI: 10.1039/d5ra03586d

rsc.li/rsc-advances

1. Introduction

Chrysanthemum indicum (Asteraceae), a perennial herb widely utilized in traditional Chinese medicine, has been historically prescribed for treating inflammatory disorders, hypertension, and respiratory diseases.^{1,2} Modern pharmacological studies have validated its ethnomedicinal applications, revealing that *C. indicum* extracts possess multifaceted bioactivities, including anti-inflammatory,³ antioxidant,⁴ antimicrobial,⁵ and anti-cancer properties.^{1,2,5} Notably, its anti-inflammatory efficacy is attributed to the suppression of pro-inflammatory cytokines

and modulation of the nuclear factor κ B (NF- κ B) signaling pathway.⁶ These pharmacological effects are predominantly mediated by bioactive constituents such as sesquiterpenes,^{7–9} flavonoids,¹⁰ and phenolic acids.¹¹ Among these, guaiane-type sesquiterpenes have garnered significant attention due to their distinctive chemical scaffolds and potent anti-inflammatory efficacy.^{12–15}

As previously reported,¹⁵ LC-MS/MS is effective in isolating guaianolides from *C. indicum* extracts. In this study, the 95% ethanol extract of *C. indicum* was fractionated using a petroleum ether (PE)/ethyl acetate (EA) gradient. LC-MS analysis revealed varying distributions of guaiane-type sesquiterpenes, with higher abundance detected in the PE/EA (2 : 1 and 1 : 1) fractions. Additionally, eleven purified compounds were isolated from the 95% ethanol extract through gradient PE/EA fractionation, including eight guaianolide-type sesquiterpenoids (1–3 being undescribed, and 5–9 being known), two caryolane-type sesquiterpenoids (10 and 11), and a previously undescribed triterpenoid (4) (Fig. 1). This contribution comprehensively details their isolation protocols, structural elucidation, and preliminary evaluation of NF- κ B inhibitory activity, revealing promising anti-inflammatory potential that aligns with the plant's traditional uses.

2. Results and discussion

2.1. LC-MS guided isolation

After LC-MS analysis of the extracts using different gradients of PE/EA solvent systems, the extraction ion flow chromatogram (EIC, Fig. 2) with molecular weight of 229.12 (ref. 15) was extracted from their total ion flow chromatogram (TIC). Due to the molecular structure of exact mass of m/z 229.12 (Fig. 3) as

^aGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, P. R. China. E-mail: wupeng@gzucm.edu.cn; Fax: +86-20-39358071; Tel: +86-20-39358651

^bChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, 519000, P. R. China. E-mail: gutcmzhs@hotmail.com

^cState Key Laboratory of Traditional Chinese Medicine Syndrome, State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510006, P. R. China. Fax: +86-20-81867705; Tel: +86-20-39318475

^dHenan Key Laboratory of Traditional Chinese Medicine Prescription and Syndrome Signaling & Henan International Joint Laboratory of Traditional Chinese Medicine Prescription and Syndrome Signaling, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China

^eChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd, Shenzhen 518110, P. R. China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5ra03586d>






Fig. 1 Structures of compounds 1–11.

a general guaiacolane-type sesquiterpene cleavage products, whose associated quasimolecular ion peaks (m/z 210.1039, 211.1117, 228.1145, 228.1323, 229.1223) were extracted in pure PE, PE/EA (2 : 1), PE/EA (1 : 1) as well as H₂O phase. Obviously, the extracts of PE/EA (2 : 1) and PE/EA (1 : 1) showed higher abundance of relevant ions, while the pure PE and H₂O phase extracted lower abundance of ions, and the relevant ion peaks of the pure EA site were not detected, which were presumed to

contain lower content of guaiacolane-type sesquiterpenoids, thus provide guidance for the subsequent isolation of the guaiacolane-type sesquiterpenoids (Fig. 4).

2.2. Structural elucidation

8-Seneciylchrysanolide D (1), isolated as a colorless oil, displayed a sodium adduct ion at m/z 615.2923 [$M + Na$]⁺ (calcd for




Fig. 2 EIC of m/z 229.12, representing guaiacolane-type sesquiterpene cleavage products. Samples: H₂O phase (A); PE/EA (1 : 1, v/v) extract (B); PE/EA (2 : 1, v/v) extract (C); pure PE extract (D); fraction 3 (in methanol) (E).






Fig. 3 Histogram (right) and structure (left) of m/z 229.1223 in the EIC from the PE/EA (2 : 1) extract (A). Histogram (right) and structure (left) of m/z 347.1831 ($[M + H]^+$, compound 9) in the EIC from fraction 3 (B).




Fig. 4 LC-MS-guided isolation workflow.

$C_{35}H_{44}O_8Na$, 615.2928) in HR-ESI-MS analysis, confirming the molecular formula $C_{35}H_{44}O_8$ ($\Omega = 14$). The IR spectrum revealed the presence of hydroxyl (3516 cm^{-1}), carbonyl (1759 cm^{-1}), and olefinic ($1653, 1446\text{ cm}^{-1}$) functionalities. The ^1H -NMR and ^{13}C NMR spectra (Table 1) exhibited 35 carbon signals, including four methyl singlets at δ_{H} 1.21 (3H, s, H-14), δ_{H} 1.29 (3H, s, H-14'), δ_{H} 1.45 (3H, s, H-15') and δ_{H} 1.89 (3H, s, H-15), three oxygenated methines ($\delta_{\text{C/H}}$ 69.2/5.51, 79.2/3.95 and 79.2/4.09), two oxygenated tertiary carbons (δ_{C} 73.0 and 73.6), an exocyclic double bond (δ_{H} 5.31, d, $J = 3.6\text{ Hz}$, 6.03, d, $J = 3.6\text{ Hz}$; δ_{C} 118.4, 141.4), two carbonyl carbons (δ_{C} 170.4 and 178.2) and characteristic signals for a senecioid moiety. The senecioid moiety shows two methyl groups at δ_{H} 2.08 (3H, d, $J = 1.2\text{ Hz}$, $\text{CH}_3\text{-4''}$) and δ_{H} 1.88 (3H, s, $\text{CH}_3\text{-5''}$), along with an olefinic proton signal at δ_{H} 5.64 (1H, m, H-2''), in conjunction with ^{13}C -NMR signals at δ_{C} 165.4 (C-1''), 115.2 (C-2''), 161.7 (C-3''), 20.6 (C-4''), and 27.8 (C-5''). The NMR data were nearly identical to those of chrysanolide D,¹⁶ except for an additional senecioid group at C-8, as confirmed by the HMBC correlation (Fig. 5) between δ_{H} 5.51 (H-8) and δ_{C} 165.4 (C-1''). The ^1H - ^1H COSY spectrum revealed four isolated spin-coupling systems of H-2'/H-3, H-5/H-6/H-7/H-8/H₂-9, H-2'/H-3' and H-5'/H-6'/H-7'/H₂-8'/H₂-9'. Furthermore, HMBC (H-15'/C-11; H-13a, H-13b/C-1', C-4', C-10') correlations suggested that the two guaianolide units are connected through C-13 to C-1' and C-11 to C-4'. These spectral

features suggested that compound 1 is a guaianolide-type sesquiterpene dimer.

The relative configuration of 1 was established through a combination of NOESY correlations, biogenetic pathway and J -based configurational analysis. As guaianolide sesquiterpene lactones characteristically contain both cyclopentane and α -methylene- γ -butenolide moieties, their dimers are primarily formed *via* enzymatically catalyzed Diels-Alder reactions.¹⁷ Following the Geissman rule, the H-7 proton was determined to be α -oriented.^{12,18} NOESY (Fig. 6) experiment revealed key spatial relationships: H-7/H-5, H-5/H-1, H-5'/H-7', H-7/H-5', H-8/H-6, H-8/H₂-13, H-6/H₃-14', H-6/H₃-15', H-2'/H-6', H₃-15'/H-6', H-6'/H₃-15, H₃-14/H-9a and H-9a/H₃-15'. The coupling constant ($J_{\text{H-6/H-7}} = 10.0\text{ Hz}$) indicated that these protons occupy an axial position on opposite sides of the molecule; thus, H-6 were deduced to have a β -orientation. The observable NOESY correlation of H-7/H-5, H-5/H-1, H-5'/H-7' and H-7/H-5', supported their cofacial spatial arrangement, confirming their α -orientation. In contrast, the NOESY cross-peaks of H-8/H-6, H-8/H₂-13, H-6/H₃-14', H-6/H₃-15', H-2'/H-6', H-15'/H-6', H-6'/H₃-15, H₃-14/H-9a and H-9a/H₃-15' established the β -orientation of H-6, H-8, H-6', $\text{CH}_2\text{-13}$, $\text{CH}_3\text{-14}$, $\text{CH}_3\text{-14'}$, $\text{CH}_3\text{-15}$ and $\text{CH}_3\text{-15'}$. The β -orientation of the $\text{CH}_2\text{-13}$, providing key evidence for determining the absolute configuration of the spiro center at C-11. Similarly, the β -orientation of H-2' was used to assign the absolute configuration of C-1'.

The absolute configuration of compound 1 was determined through comparison of its experimental electronic circular dichroism (ECD) spectrum (Fig. 7) with the theoretically calculated ECD spectrum as (1R,5R,6R,7R,8S,10R,11R,1'R,4'R,5'S,6'S,7'S,10'R). Accordingly, the structure of compound 1 was unequivocally established and named 8-senecioidylchrysanolide D.

Chrysanolide J (2), isolated as a colorless oil, its molecular formula is $C_{35}H_{42}O_8$ ($\Omega = 15$) according to HR-ESI-MS (m/z 613.2824 $[M + Na]^+$, calcd for $C_{35}H_{42}O_8Na$, 613.2822). The IR spectrum revealed the presence of hydroxyl (3488 cm^{-1}), carbonyl (1749 cm^{-1}), and olefinic (1454 cm^{-1}) functional groups. Comparative analysis with the known compound Chrysanolide C¹⁷ revealed similar NMR data, with the primary differences being the presence of a carbonyl signal at δ_{C} 207.5 (C-2) and the absence of a hydroxyl group at C-10 in compound 2. The ^1H -NMR spectrum (Table 1) exhibited signals of an angeloyl moiety for two methyl groups at δ_{H} 1.93 (3H, dd, $J = 1.2, 7.6\text{ Hz}$, $\text{CH}_3\text{-4''}$) and δ_{H} 1.85 (3H, s, $\text{CH}_3\text{-5''}$), along with an olefinic proton signal at δ_{H} 6.11 (1H, m, H-3''). The ^1H - ^1H COSY spectrum revealed five isolated spin-coupling systems of H-5/H-6/H-7/H-8/H₂-9, H-1/H-10/H₃-14, H-2'/H-3', H-5'/H-6'/H-7'/H₂-8'/H₂-9' and H-3''/H-4''. HMBC (H-1, H-3, H-5/C-2) correlations (Fig. 5) confirmed the presence of a carbonyl group at C-2. NOESY (Fig. 6) experiments revealed key spatial relationships: H-5/H-1, H-5/H-7, H-6/H-8, H-6/H₃-14, H-8/H₂-13, H₂-13/H₃-14', H-2'/H-6', H₃-15'/H-6', H₃-14'/H₃-15', H-7/H-5', and H-5'/H-7'. Based on an accepted principle that H-7 is generally α -oriented in natural guaianolides, and three diagnostic coupling constants ($J = 9.6\text{ Hz}$ for H-6/H-7, H-5/H-6, and H-6'/H-7') revealed *trans*-diaxial for these three pairs of protons.

Table 1 NMR spectroscopic data of compounds 1–3^a

No.	1		2		3	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}
1	2.57 (1H, m)	54.4	2.86 (1H, m)	56.3	2.53 (1H, m)	58.8
2	2.15 (1H, m); 2.04 (1H, m)	33.4	—	207.5	4.26 (1H, d, 6.0)	85.9
2-OCH	—	—	—	—	3.32 (3H, s)	56.2
3	5.49 (1H, m)	125.8	5.93 (1H, overlap)	134.6	5.72 (1H, m)	126.7
4	—	145.0	—	177.4	—	147.1
5	2.74 (1H, m)	54.8	3.02 (1H, dd, 9.6, 6.4)	54.8	3.07 (1H, dd, 9.6, 9.2)	54.0
6	3.95 (1H, dd, 10.4, 10.0)	79.2	3.81 (1H, dd, 10.0, 9.6)	80.8	3.93 (1H, dd, 10.8, 9.6)	81.5
7	3.43 (1H, dd, 10.0, 8.4)	48.3	3.12 (1H, dd, 9.6, 9.6)	47.5	3.80 (1H, m)	47.5
8	5.51 (1H, m)	69.2	5.41 (1H, m)	70.3	5.22 (1H, m)	72.1
9	2.24 (1H, m); 1.98 (1H, m)	38.4	1.76 (2H, m)	36.2	2.33 (1H, dd, 5.2, 16.0), 1.98 (1H, d, 4.4)	43.4
10	—	73.6	2.46 (1H, m)	26.9	—	73.1
11	—	58.6	—	59.8	—	137.8
12	—	178.2	—	177.7	—	169.5
13	2.37 (1H, d, 12.0), 1.48 (1H, m)	37.3	2.34 (1H, m), 1.52 (1H, m)	37.9	6.22 (1H, m), 5.58 (1H, d, 3.2)	122.4
14	1.21 (3H, s)	33.7	1.37 (3H, d, 7.2)	21.5	1.30 (3H, s)	31.8
15	1.89 (3H, s)	18.5	2.27 (3H, s)	20.7	1.95 (3H, s)	18.1
1'	—	64.6	—	65.0	—	167.0
2'	6.22 (1H, d, 5.6)	141.0	6.08 (1H, d, 5.2)	139.6	—	127.2
3'	5.87 (1H, d, 5.6)	133.6	5.94 (1H, m)	131.6	6.20 (1H, m)	140.3
4'	—	57.5	—	56.6	2.04 (1H, dd, 1.6, 7.2)	16.1
5'	1.92 (1H, m)	65.8	2.15 (1H, m)	66.3	1.93 (1H, m)	20.8
6'	4.09 (1H, dd, 10.0, 9.6)	79.2	4.07 (1H, dd, 9.6, 9.6)	79.4	—	—
7'	3.01 (1H, m)	43.1	3.01 (1H, dd, 9.6, 6.4)	43.2	—	—
8'	2.20 (1H, d, 4.4), 1.44 (1H, m)	23.9	2.17 (1H, m), 1.44 (1H, m)	23.7	—	—
9'	1.81 (2H, m)	35.0	1.81 (2H, m)	34.9	—	—
10'	—	73.0	—	72.7	—	—
11'	—	141.4	—	141.0	—	—
12'	—	170.4	—	170.3	—	—
13'	6.03 (1H, d, 3.6), 5.31 (1H, d, 3.6)	118.4	6.05 (1H, d, 3.2), 5.33 (1H, d, 3.2)	118.7	—	—
14'	1.29 (3H, s)	29.9	1.29 (3H, s)	29.9	—	—
15'	1.45 (3H, s)	15.5	1.48 (3H, s)	15.6	—	—
1''	—	165.4	—	166.7	—	—
2''	5.64 (1H, m)	115.5	—	127.4	—	—
3''	—	161.7	6.12 (1H, m)	141.6	—	—
4''	2.08 (1H, d, 1.2)	20.6	1.93 (3H, dd, 1.2, 7.6)	16.2	—	—
5''	1.88 (1H, d, 1.2)	27.8	1.85 (3H, s)	20.6	—	—

^a δ in ppm; J in Hz; in CDCl₃. ¹H-NMR data (δ) were measured at 400 MHz; ¹³C-NMR data (δ) were measured at 100 MHz.




Fig. 5 Selected HMBC (arrow) and ¹H–¹H COSY (bold) correlations of compounds 1–4.




Fig. 6 Selected NOESY (arrow) correlations of compounds 1–4.






Fig. 7 ECD spectra of compounds 1–3.

Collectively, these data established the α -orientation of H-1, H-5, H-7, H-5', and H-7', while H-6, H-8, CH₂-13, CH₃-14, H-2', H-6', CH₃-14', and CH₃-15' were determined to be β -oriented. The absolute configuration of compound 2 was determined through comparison of its experimental ECD spectrum (Fig. 7) with the theoretically calculated ECD spectrum as (1*S*,5*R*,6*R*,7*R*,8*S*,10*S*,11*R*,1'*R*,4'*R*,5'*S*,6'*S*,7'*S*,10'*R*)-2.

8-Angeloyl-2-methoxy-10-hydroxy-3,11(13)-guaia-12,6-olide (3), isolated as a colorless oil, its molecular formula is C₂₁H₂₈O₆ (Ω = 8) according to HR-ESI-MS (m/z 399.1764 [M + Na]⁺, calcd for C₂₁H₂₈O₆Na, 399.1770). IR spectroscopy indicated the presence of hydroxyl (3510 cm⁻¹), carbonyl (1741 cm⁻¹), and double bond (1454 cm⁻¹) functional groups. Comparison with the known compound 8-acetoxy-2-methoxy-10-hydroxy-3,11(13)-guaia-12,6-olide,¹⁹ showed similar spectroscopic data, with the main difference being the substituent at C-8. The ¹H-¹H COSY spectrum revealed three isolated spin-coupling systems of H-2/H-3, H-5/H-6/H-7/H-8/H₂-9 and H-3''/H-4''. HMBC spectra (Fig. 5) showed that δ_{H} 5.22 (H-8) was remotely correlated with δ_{C} 167.0 (C-1'), suggesting that an angelica acyl group was attached at the C-8. NOESY correlations (Fig. 6) (H-5/H-1, H-5/H-7, H-6/H-8, H-14/H-2, H-14/H-6) suggested that H-1, H-5, and H-7 are α -oriented, while H-2, H-6, H-8, and H-14 are β -oriented. The absolute configuration of compound 3 was determined to be (1*S*,2*S*,5*R*,6*R*,7*R*,8*S*,10*R*) (Fig. 7).

16,22,23,28-Tetrahydroxyolean-12-ene (4) was isolated as a white powder, HR-ESI-MS analysis showed a molecular ion peak at m/z 475.3864 [M]⁺ (calcd for C₃₀H₅₀O₄, 475.3857), thus the molecular formula was deduced to be C₃₀H₅₀O₄ (Ω = 6). IR spectroscopy indicated the presence of hydroxyl (3425 cm⁻¹) and double bond (1689 cm⁻¹, 1460 cm⁻¹) functional groups. The ¹H-NMR spectrum (Table 2) revealed six methyl proton signals (δ_{H} 0.93, 0.95, 0.98, 1.03, 1.16, and 1.43), two oxygenated methylene signals (δ_{H} 3.66, H-23a and δ_{H} 3.44, H-23b, J = 11.2 Hz; δ_{H} 3.61, H-28a and δ_{H} 3.32, H-28b, J = 10.8 Hz), two oxygenated methine proton signals (δ_{H} 4.03, 4.67), while a double bond proton signal was observed at δ_{H} 5.29 (1H, brs) in the downfield region. In the ¹³C-NMR spectrum (Table 2), four oxygenated carbon signals were observed at δ_{C} 67.2, 68.3, 76.7, and 73.2, while a pair of double bond carbon signals appeared at δ_{C} 122.8 and 142.7. These data suggested that compound 4 is a Δ^{12} -oleanene-type triterpenoid. Compound 4 showed similar spectroscopic data to the known compound gymnemanol,²⁰ with the main difference being the absence of a hydroxyl group

at C-3. In the ¹H-¹H COSY spectrum, the following correlations (Fig. 5) were observed: δ_{H} 5.29 (H-12) with δ_{H} 1.94 (H-11); δ_{H} 2.04/1.45 (H-15) with δ_{H} 4.67 (H-16); and δ_{H} 1.77/1.58 (H-21) with δ_{H} 4.03 (H-22). HMBC (H-23/C-24, H-23/C-5, H-28/C-16, H-28/C-18, H-28/C-22, H-22/C-16) correlations (Fig. 5) indicated hydroxyl substitutions at C-16 and C-22, and the formation of -CH₂OH structures at C-24 and C-28 due to hydroxylation of the angular methyl groups. NOESY correlations (Fig. 6) (H-5/H-9, H-5/H₃-23, H-9/H₃-27, H-16/H₃-27) suggested that H-5, H-9, H-16, CH₃-23, and CH₃-27 are α -oriented, while correlations between H-28/H-22 and H₃-25/H₃-26 indicated that H-22, CH₃-25, and CH₃-26 are β -oriented.

Table 2 NMR spectroscopic data of compound 4^a

No.	δ_{H}	δ_{C}
1	1.94 (1H, m), 1.40 (1H, m)	39.1
2	2.63 (1H, m), 2.29 (1H, m)	35.4
3	1.25 (2H, m)	29.8
4	—	52.6
5	1.64 (1H, m)	49.3
6	1.45 (1H, m), 1.55 (1H, m)	19.3
7	1.67 (1H, m), 1.42 (1H, m)	32.3
8	—	39.9
9	1.77 (1H, m)	45.9
10	—	36.6
11	1.94 (2H, m)	23.7
12	5.29, brs	122.8
13	—	142.7
14	—	41.9
15	2.04(1H, m), 1.45(1H, m)	33.8
16	4.67, brs	68.3
17	—	44.0
18	1.94 (1H, m)	42.5
19	2.27 (1H, m), 1.08 (1H, m)	47.4
20	—	31.5
21	1.77 (1H, m), 1.58 (1H, m)	45.9
22	4.03, dd, 12.4, 6.0	76.7
23	3.66(1H, d, 11.2), 3.44(1H, d, 11.2)	67.2
24	1.03(3H, s)	17
25	1.16 (3H, s)	15.6
26	0.98 (3H, s)	17.0
27	1.43 (3H, s)	27.1
28	3.61 (1H, d, 10.8), 3.32 (1H, d, 10.8)	73.2
29	0.93 (3H, s)	33.2
30	0.95 (3H, s)	24.9

^a δ in ppm; J in Hz; in CDCl₃. ¹H-NMR data (δ) were measured at 400 MHz; ¹³C-NMR data (δ) were measured at 100 MHz.



Apart from four previously undescribed compounds, the other known compounds were isolated and identified as handelin (5),²¹ 8-tigloylchrysanolide D (6),¹⁶ chrysanolide C (7),¹⁷ cumambrin A (8),²¹ angeloylcumambrin B (9),²² caryolane-1 β ,9 β -diol (10),²³ (-)-clovane-2,9-diol (11) (Fig. 1).²⁴

2.3. LC-MS/MS validation of isolated compounds

To verify the presence of both previously undescribed compounds and known compounds in the original plant material and their enrichment in fractions, LC-MS/MS analysis was conducted. Multiple structural isomers with the molecular formula C₃₅H₄₄O₈ (*m/z* 590.30) were identified in *C. indicum* extracts, notably, EIC (Fig. 8) analysis of C₃₅H₄₄O₈ revealed consistent co-elution of compounds 1 and 6 in both crude extract and fraction 5.

2.4. Biological activity

2.4.1. Screening result of anti-inflammatory activity. The NF- κ B nuclear translocation in LPS-stimulated RAW264.7 cells was detected by high-content imaging (HCI) to evaluate the anti-inflammatory activity of compounds 1–11. The results showed that compounds 2, 8 and 9 had an inhibitory effect on NF- κ B nuclear translocation in LPS-induced RAW264.7 cells at 10 μ M, which was similar to the positive drug BAY11-7085 (Fig. 9A and B), indicating that compound 2, 8 and 9 can be chosen as the anti-inflammatory candidates for further study.

2.4.2. Cell cytotoxicity of candidate compounds. To explore the further anti-inflammatory effect, the cytotoxicity of compounds 2, 8 and 9 was detected. Through the detection of MTT and HCI methods, we determined that compound 2, 8 and 9 had certain cytotoxicity on RAW264.7 cells without/with LPS (Fig. 10A–F). And compound 2, 8 and 9 had no significant

cytotoxicity to RAW264.7 cells at the concentration of 20 μ M, 6.25 μ M and 6.25 μ M, respectively (Fig. 10G–I).

2.4.3. Inhibition curve and IC₅₀ of candidate compounds.

The inhibition curve of NF- κ B nuclear translocation of compounds 2, 8 and 9 were detected in the LPS-stimulated RAW264.7 cell model. As shown in Fig. 11, compounds 2, 8 and 9 suppressed NF- κ B nuclear translocation in a dose-dependent manner in the LPS-stimulated RAW264.7 cell model. Furthermore, their IC₅₀ values were 9.70, 2.04 and 1.21 μ M, respectively.

3. Experimental

3.1. Plant material

The aerial parts of *C. indicum* were collected in Yangxin *Chrysanthemum indicum* L. Cultivation Base, Hubei, China in 2019. The samples (Batch no. 20190719) were identified by Min Wei, an engineer of China Resources Sanjiu Pharmaceutical Company Limited, and preserved in the International Institute of Translational Medicine of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.

3.2. LC-MS analysis

3.2.1. General experimental procedures of LC-MS/MS analysis. The samples were analysed on a Waters ACQUITY UPLC HSS C18 column (1.8 μ m, 2.1 mm \times 100 mm) on an Agilent 6540 UPLC-Q-TOF-MS (Agilent, California, USA) equipped with Dual AJS ESI. Mobile phase gradient was selected: (a) 0–20 min: 10–90% B, methodological analysis for LC-MS-guided fractionation; (b) 0–20 min: 20–100% B, methodological analysis for compound identification *via* LC-MS/MS; flow rate: 0.3




Fig. 8 EIC about molecular formula of C₃₅H₄₄O₈ (exact mass of *m/z* 590.30). Samples: compound 1 (A); compound 6 (B); fraction 5 (C); *C. indicum* crude extract (D).






Fig. 9 Inhibitory effect of compounds 1–11 from *C. indicum* on NF-κB nuclear translocation in LPS-induced RAW264.7 cells. RAW264.7 cells were seeded at 10 000 cells per well in 96-well plate overnight, and then treated with 10 μM of 11 compounds for 40 minutes followed by 200 ng mL⁻¹ LPS stimulation for 40 minutes. The NF-κB nuclear translocation (green) was detected by HCl. The screening result of compound 1–11 on NF-κB nuclear translocation in LPS-induced RAW264.7 cells was detected by HCl (A). The NF-κB translocation was normalized to the LPS group data (100%) and control data (0%). The results are presented as means ± S.E, *n* = 3. The representative HCl images of LPS-induced RAW264.7 cells treated without or with compound 2, 8 and 9 (B). Scale bar: 50 μm. [^]*P* < 0.01 vs. control alone, [^]*P* < 0.01 vs. LPS alone.

mL min⁻¹; column temperature: 40 °C. Mobile phase A was 0.1% aqueous formic acid and B was acetonitrile (ACN), analysed in positive ion mode. The mass spectral data were recorded in the range of 50–1700 *m/z*. An internal mass calibration was performed using reference masses of 121.0509 (purine) and 922.0098 (HP-0921) when running in positive ion mode. The running parameters were as follows: drying N₂ gas flow rate: 8 L min⁻¹; temperature: 320 °C; nebulizer: 35 psig; capillary: 3500 V; skimmer: 65 V; OCT RfV: 750 V; fragmentor: 175 V.

3.2.2. Preparation of extracts for analysis. The crude extract (0.4 g) obtained from the aerial parts of *C. indicum* was suspended in water, and then extracted by gradient extraction with PE/EA solvent system (1 : 0, 2 : 1, 1 : 1, 0 : 1) in order. After recycling the solvent, the products were then dosed to 10 mL with methanol. And all of them were filtered with 0.22 μm filter membrane as the samples for LC-MS analysis.

3.2.3. Procedure for LC-MS/MS structural verification. Samples (crude extract, fractions, and isolated compounds) were dissolved in HPLC-grade methanol, filtered through 0.22 μm membranes, and analysed using identical gradient elution condition. Full-scan MS and MS/MS analyses were performed to obtain both molecular ions and fragmentation patterns. Target compounds were identified by extracting their characteristic molecular ion peaks from the TIC.

3.3. General experimental procedures of isolation and structure elucidation

UV spectra were measured using a JASCO V-730 UV-vis spectrophotometer (Jasco, Tokyo, Japan), IR spectra were obtained using a JASCO FT/IR-4600 spectrophotometer (Jasco, Tokyo, Japan), and HR-ESI-MS data were acquired using an Agilent 6540 UPLC-Q-TOF-MS (Agilent, California, USA). NMR data were acquired using a Bruker AV-400 MHz NMR spectrophotometer (Bruker, Faellanden, Switzerland) in CDCl₃ (Sigma-Aldrich, USA), with tetramethylsilane as the internal standard. ECD spectra were available on a Chirascan circular dichroism (Applied Photophysics, UK). Semi-preparative HPLC separations were carried out on an HPLC (Shimadzu, Japan) on an Inertsil PREP-ODS (10 μm, 20 × 250 mm) column (GL Sciences Inc., Eindhoven, the Netherlands), and analysed and purified by HPLC on a COSMOSIL (5 μm, 4.6 × 150 mm) column (Nacalai Tesque, Japan). Silica gel (100–200, 200–300, 300–400 mesh, Qingdao Ocean Chemical Factory, China), Sephadex LH-20gel (25–100 μm, Fluka, Sweden), MCI (Mitsubishi Chemical Corporation, Japan), and ODS (YMC Corporation, Kyoto, Japan) were used for the column chromatography (CC) analysis. Silica gel thin-layer plates (GF₂₅₄, Qingdao Ocean Chemical Factory, Qingdao, China), vanillin (Tianjin Komeo Company, Tianjin, China), and concentrated sulfuric acid (AR, Shanghai energy Chemical Co., Ltd, Shanghai, China) were used for thin-layer






Fig. 10 The cell cytotoxicity of compounds **2**, **8** and **9** in with/without LPS-stimulated RAW264.7 cells by MTT and HCl. RAW264.7 cells were seeded at 8000 cells per well in 96-well plates overnight, and then treated with different concentrations of compounds **2**, **8** and **9** for 1 h followed with or without 200 ng mL⁻¹ LPS for 18 h. Cell viability of compounds in with/without LPS-stimulated RAW264.7 cells was analyzed by MTT (A–C) and HCl (D–F). The cell viability of control group was set to 100% and the results were presented as means \pm S.E., $n = 3$. (G–I) The representative cell cytotoxicity HCl images of compounds **2**, **8** and **9**. Scale bar: 100 μ m. $^{**}P < 0.01$, $^{***}P < 0.001$ vs. LPS alone.

chromatography (TLC) analysis. Solvents used for analysis and preparation on HPLC were of HPLC grade (Merck, USA), and the others used for CC were of AR grade (Shanghai energy chemical Co.)

3.4. Extraction and isolation

After crushing the dried *C. indicum* stems and leaves (17 kg), the crude powder (40–60 mesh) obtained was extracted by maceration with 95% ethanol (50 L in total) at room temperature (3 days \times 3 times). The combined extracts were concentrated under reduced pressure until they were flavorless without alcohol to obtain a crude extract (500 g). The crude extract was eluted with a gradient of PE/EA (100:0–0:100) on a column chromatography of silica gel (100–200 mesh) to obtain seven fractions (1–7).




Fig. 11 The IC₅₀ values of compounds **2**, **8** and **9** on NF- κ B nuclear translocation in LPS-stimulated RAW264.7 cells (A–C). RAW264.7 cells were seeded at 8000 cells per well in 96-well plates overnight, and then treated with or without compounds **2**, **8** and **9** for 1 h followed with or without 200 ng mL⁻¹ LPS for 40 minutes. NF- κ B nuclear translocation was analysed by HCl. The NF- κ B nuclear translocation of LPS group was set to 100% and control data was set 0%. The results are presented as means \pm S.E., $n = 3$.

Fraction 3 (70 g, PE/EA, 96:4–7:3) was loaded on a silica gel (200–300 mesh) column eluting with a *n*-hexane–ethyl acetate gradient (100:0–1:1) to obtain eleven flow fractions (3A–3K), and Fr.3H (5 g, *n*-Hex/EA, 10:1–5:1) continued to be purified on a silica gel (300–400 mesh) column with elution of PE/EA (100:0–1:1), resulting in four subfractions (3H-1–3H-4), and Fr.3H-3 (PE/EA, 15:1–10:1) was again purified over a silica gel (300–400 mesh) column to obtain Fr.3H-3A–Fr.3H-3D, the oil on the bottle wall of Fr.3H-3C was taken out as YJ-3H-3C₂ alone, and was prepared by analytical HPLC to obtain compound **9** (5 mg, ACN/H₂O, 60:40, $t_R = 22.8$ min, 1 mL min⁻¹).

Fr.5 (24.31 g, PE/EA, 6:4–4:6), eluting its upscaled silica gel (200–300 mesh) column by a gradient of *n*-Hex/EA (9:1–1:1) yielded nine fractions (5A–5I), the Fr.5E (5.5 g, *n*-Hex/EA, 8:2) was given to 7 subfractions (5E-11–5E-7) by a silica gel (200–300 mesh) column eluting its up-loading through a PE/EA (7:1–0:10) gradient. Fr.5E-5 (1.6 g, PE/EA, 3:1) was converted to an *n*-Hex/EA (10:1–0:10) solvent system on a silica gel (300–400 mesh) column to purify another 7 fractions (5E-5A–5E-5G). Among them were identified by thin-layer chromatography and vanillin-concentrated sulfuric acid chromatography, all of which contained blue spots combined as Fr.5E-5F (*n*-Hex/EA, 4:1–3:1). Fr.5E-5F was purified on an ODS column with a gradient of MeOH/H₂O (10:90–100:0) to obtain 12 fractions (5E-5F-1–5E-5F-12). Finally, Fr.5E-5F-4 (MEOH/H₂O 45:55–50:50) was used to obtain compound **8** (30.5 mg, ACN/H₂O, 40:60, $t_R = 26.5$ min, 1 mL min⁻¹) by analytical HPLC. Fr.5G (6.5 g, *n*-Hex/EA, 3:1), over a silica gel (300–400 mesh) column eluted with PE/EA (6:1–0:10) yielded 10 subfractions (5G-1–5G-10), and Fr.5G-8 (PE/EA, 3:1) was purified on an ODS column with MeOH/H₂O (30:70–100:0) gradient elution, and the 21st sample bottle obtained through a Sephadex LH-20 column under an isocratic eluent of DCM/MeOH (1:1) and was given to four subfractions (5G-8-21-A–5G-8-21-D), of which Fr.5G-8-21-A



was used on analytical HPLC, and the sample was separated on an ACN/H₂O (60 : 40) gradient to obtain compounds **6** (6 mg, t_R = 27.0 min, 1 mL min⁻¹), **1** (1 mg, t_R = 27.5 min, 1 mL min⁻¹), and **7** (7.7 mg, t_R = 31.0 min, 1 mL min⁻¹) sequentially.

Fr.6 (25 g, PE/EA, 4 : 6–0 : 10) eluted with DCM/Me (100 : 1–1 : 1) gradient silica gel (200–300 mesh) column yielded 9 fractions (6A–6I), Fr.6D (1 g, DCM/ME, 100 : 1) eluted with PE/EA (100 : 1–2 : 1) gradient silica gel (300–400 mesh) column, leading to the separation of 9 subfractions (6D-1–6D-9), Fr.6D-6 (PE/EA, 4 : 1) was eluted with DCM/ME (1 : 1) isocratic elution of its up-sampling of Sephadex LH-20 column, the purified Fr.6D-6A was obtained, and the next analytical column was used to obtain by analytical HPLC the compound **5** (10 mg, ACN/H₂O, 45 : 55, t_R = 21.9 min, 1 mL min⁻¹). Fr.6E (DCM/ME, 100 : 1–50 : 1) over PE/EA (10 : 0–0 : 10) gradient eluted silica gel (300–400 mesh) columns to obtain 7 subfractions (6E-1–6E-7), of which Fr.6E-3 (PE/EA, 3 : 1) over MeOH/H₂O (50 : 50–100 : 0) gradient elution of the ODS column led to Fr.6E-3A–Fr.6E-3H, of which the sample of vial 7 and 8 was Fr.6E-3B (MeOH/H₂O, 90 : 10), Fr.6E-3B was used to obtain compound **3** by analytical HPLC (4.3 mg, ACN/H₂O, 40 : 60, t_R = 33.8 min, 1 mL min⁻¹); Fr.6 × 10⁻⁵ (PE/EA, 3 : 1–2 : 1) over MeOH/H₂O (30 : 70–100 : 0) gradient elution of the ODS column to obtain Fr.6E-5A–Fr.6E-5J, Fr.6E-5H (MeOH/H₂O, 80 : 20) was purified by analytical HPLC to obtain compound **2** (1 mg, ACN/H₂O, 55 : 45, t_R = 30.0 min, 1 mL min⁻¹). Fr.6F (DCM/ME, 50 : 1–20 : 1) was eluted with MeOH/H₂O (30 : 70–60 : 40) on an ODS column under a gradient to obtain Fr.6F-1–Fr.6F-7, of which Fr.6F-6 and Fr.6F-7 eluted from 60% methanol were recognized by thin-layer chromatography as uniform purple spots. Both fractions were further purified by isocratic elution with DCM/Me (1 : 1) on a Sephadex LH-20 column, and the resulting Fr.6F-6B and Fr.6F-7A were prepared by analytical HPLC to obtain the compounds **10** (25 mg, ACN/H₂O, 30 : 70, t_R = 34.8 min, 1 mL min⁻¹) and **11** (5.5 mg, ACN/H₂O, 35 : 65, t_R = 22.8 min, 1 mL min⁻¹), respectively.

Fr.7 (19.73 g, pure EA) was subjected to a silica gel (200–300 mesh) column eluted by a gradient of DCM/Me (99 : 1–0 : 100) to give 7 fractions (7A–7G), and Fr.7C (2.73 g, DCM/ME 98 : 2–97 : 3) was eluted on an MCI column with MeOH/H₂O (20 : 80–100 : 0) gradient elution to obtain four subfractions (7C-1–7C-4), Fr.7C-4 (MeOH/H₂O, 70 : 30–100 : 0) was isocratically eluted with DCM/Me (1 : 1) on its up-loading Sephadex LH-20 column to obtain Fr.7C-4A–Fr.7C-4F, Fr.7C-4C was purified by semi-preparative HPLC to give compound **4** (23 mg, ACN/H₂O, 75 : 25, t_R = 35.0 min, 3 mL min⁻¹).

8-Seneciylchrysanolide D (**1**): colorless oil; $[\alpha]_D^{25.1}$ = -4.2 (c = 0.1, MeOH); IR (KBr) ν_{\max} : 3516, 2931, 1759, 1653, 1446 cm⁻¹; UV (MeOH) λ_{\max} : 198 nm; ECD (MeOH) λ_{\max} ($\Delta\epsilon$): 200 (+13.0), 221 (-12.8) nm; NMR spectroscopic data (CDCl₃, 400/100 MHz), see Table 1; HR-ESI-MS m/z 615.2923 [M + Na]⁺ (calcd for C₃₅H₄₄O₈Na, 615.2928).

Chrysanolide J (**2**): colorless oil; $[\alpha]_D^{25.1}$ = -4.0 (c = 0.1, MeOH); IR (KBr) ν_{\max} : 3489, 2927, 1749, 1454, 1373 cm⁻¹; UV (MeOH) λ_{\max} : 200 nm; ECD (MeOH) λ_{\max} ($\Delta\epsilon$): 200 (+15.0), 208 (-19.8), 228 (+5.0) nm; NMR spectroscopic data (CDCl₃, 400/100

MHz), see Table 1; HR-ESI-MS m/z 613.2824 [M + Na]⁺ (calcd for C₃₅H₄₂O₈Na, 613.2822).

8-Angeloyl-2-methoxy-10-hydroxy-3,11(13)-guaidiene-12,6-olide (**3**): colorless oil; $[\alpha]_D^{25.1}$ = +13.0 (c = 0.1, MeOH); IR (KBr) ν_{\max} : 3510, 2945, 2866, 1741, 1454 cm⁻¹; UV (MeOH) λ_{\max} : 198 nm; ECD (MeOH) λ_{\max} ($\Delta\epsilon$): 200 (+9.0), 212 (+0.1), 241 (+5.0) nm; NMR spectroscopic data (CDCl₃, 400/100 MHz), see Table 1; HR-ESI-MS m/z 399.1764 [M + Na]⁺ (calcd for C₂₁H₂₈O₆Na, 399.1770).

16,22,23,28-Tetrahydroxyolean-12-ene (**4**): white powder; $[\alpha]_D^{25.1}$ = +3.6 (c = 0.1, MeOH); IR (KBr) ν_{\max} : 3425, 3925, 1689, 1460, 1065 cm⁻¹; UV (MeOH) λ_{\max} : 199 nm; NMR spectroscopic data (CDCl₃, 400/100 MHz), see Table 2; HR-ESI-MS m/z 475.3864 [M]⁺ (calcd for C₃₀H₅₀O₄, 475.3857).

3.5. ECD spectral computation

The initial conformations of two possible configurations for compounds **1–3** were constructed based on its NOESY correlations. Conformational searches were performed using the MMFF94s force field in SYBYL 8.1, with low-energy conformations within a 10 kcal mol⁻¹ energy window collected to form an initial conformational ensemble. These preliminary conformations were subsequently optimized at the DFT (B3LYP)/6-31+G(d) level of theory in Gaussian 09. Further refinement selected conformations within a 3 kcal mol⁻¹ energy cutoff to generate a stable conformational ensemble. Finally, ECD spectra for all stable conformers were calculated using time-dependent DFT (TDDFT) with the following parameters: TD (singlet, nstate = 50) scrf (solvent = methanol). Theoretical ECD spectra were generated by Boltzmann-weighted averaging based on thermodynamic statistics, employing the CPCM solvation model (methanol as solvent).

3.6. Cells and treatments

The murine macrophages RAW264.7 cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Grand Island, New York, USA) supplemented with 10% heat-inactivated FBS (Gibco BRL Co, Grand Island, NY, USA), penicillin G (100 units per ml), streptomycin (100 µg mL⁻¹), and L-glutamine (2 mM) (Gibco BRL Co, Grand Island, NY, USA). The cells were grown at 37 °C in a humidified atmosphere with 5% CO₂. Compounds **1–11** were dissolved in DMSO and the final concentration is 20 mM. Pretreated the cells with the tested compounds and then stimulated with LPS. At the end of incubation, the anti-inflammatory activity was evaluated by assessing NF-κB translocation and cell viability. The cells stimulated by LPS without any intervention were used as model control. The cells incubated with DMEM medium were used as normal control.

3.7. Measurement of NF-κB nuclear translocation

The NF-κB nuclear translocation was detected using a previously described HCl method.²⁵ The cells were seeded in 96-well plates at a density of 1.0 × 10⁴ cells per well for 18 h. The cells were then respectively pretreated with compounds (10 µM) and



BAY-117085 (1 μM) for 1 h. Afterward, the cells were stimulated with or without LPS (200 ng mL^{-1}) for 40 minutes. The cells were fixed with 4% paraformaldehyde solution for 15 minutes, permeabilized with 0.2% Triton-100X for 15 minutes, blocked with 3% BSA for 30 minutes, stained with a 1 : 500 dilution of p65-FITC antibody (Santa Cruz, CA, USA) for 3 h, and with DAPI solution (Thermo Scientific, NC, USA) for 5 minutes. Finally, the plates were imaged, and the nuclear translocation of NF- κ B (green) was analysed using by HCI technology with the In Cell Analyzer 6000 imaging system (General Electric Company, Boston, USA).

3.8. Cell cytotoxicity assay

The RAW 264.7 cells were seeded at a density of 8000 cells per well in 96-well plates for 24 hours. The cells were then pre-treated with the candidate compounds (2, 8 and 9) and DMSO (0.1%). After that, the cells were stimulated with or without LPS (200 ng mL^{-1}) for 18 hours. After the treatment, different experiments were used to measure the cell viability.

MTT method was used to assess the cells cytotoxicity of compounds. After the treatment, 100 μL of MTT solution per well was added for 4 hours, which followed by 10% SDS-HCl solution for 18 hours. Then thoroughly shake the 96-well plates for 5 min. Lastly, the OD value at 570 nm and 650 nm was measured, and the OD value of control cells was set as 100%.

HCI was used to assess the cells cytotoxicity of compounds. After the treatment, the cells were stained by CalceinAM (green) and propidium iodide (red) (Beyotime Biotechnology, Shanghai, China) for 30 min at 37 $^{\circ}\text{C}$. Then the cells were washed twice by PBS. Lastly, the lived cells (green) and dead cells (red) in 96-well plates were imaged by HCI. And the cell viability of control group was set to 100%.

3.9. Statistical analysis

The NucCyto difference was used to analyze NF- κ B translocation via Nuclear Translocation Analysis on an HCS imager. The log (agonist) vs. normalized response was plotted using GraphPad Prism 7.0 software (GraphPad Software Inc, La Jolla, CA, USA). The data was expressed as the mean \pm S. M. E. of two or three independent experiments. Statistical significance comparisons between the different compound-treated groups and the model control group were analysed by one-way ANOVA followed by post hoc analyses using the SNK method in GraphPad Prism 7.0 software. Compounds with 50% inhibition of NF- κ B nuclear translocation were considered as potential candidates. *P* values less than 0.05 were considered statistically significant.

4. Conclusion

In conclusion, three previously undescribed guaiacane-type sesquiterpenes (1–3) and one triterpene compound (4) were found in the aerial parts of *C. indicum*, along with seven known sesquiterpenoids. The structures of these terpenoids were elucidated by comprehensive spectral analysis. Then, in the LPS-stimulated RAW264.7 macrophages, compounds 2, 8 and 9 at the dosage of 10 μM had shown significant inhibitory effect

on the NF- κ B translocation. In addition, they exhibited no significant cytotoxicity toward LPS-induced RAW264.7 cells at therapeutic doses. Based on these results, compounds 2, 8 and 9 may have anti-inflammatory value for in-depth research.

Data availability

The data supporting this study are included within the manuscript and its ESI† files.

Author contributions

Xinyue Li: investigation, data curation, visualization, writing-original draft, writing review & editing. Yanfen Cai: data curation, writing review & editing. Yunshuang Hu: data curation. Limei Miu: investigation & conceptualization. Yanyu Zhang: data curation, visualization, writing review & editing. Shiyun Huang: data curation & visualization. Min Wei: resources. Qing Ma: resources. Zhongqiu Liu: resources, conceptualization, supervision & funding acquisition. Hua Zhou: resources, conceptualization, supervision & funding acquisition. Peng Wu: resources, conceptualization, supervision, funding acquisition, writing review & editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research received funding from National Key Research and Development Program of China (2023YFC3502800), Joint Funds of the National Natural Science Foundation of China (No. U22A20368), Natural Science Foundation of Guangdong Province (No. 2023A1515011761), Key Laboratory of Guangdong Drug Administration (No. 2021ZDB03), Talent Support Project of Guangdong (No. 2021JC050230), the Open Research Project of State Key Laboratory of Dampness Syndrome of Chinese Medicine (No. SZ2022KF09), Guangxi Science and Technology Major Program Grant (No. GUIKEAA23023035), and Guangzhou University of Chinese Medicine College Students' Innovation and Entrepreneurship Training Program Project (No. 202410572291).

References

- G. Song, M. Choi, W. Y. Park, S. H. Kim, W. Jiao, J. Y. Park, K. S. Ahn, H. J. Kwak and J. Y. Um, *Front. Pharmacol.*, 2024, **15**, 1455805.
- Y. J. Wang, J. Su, J. J. Yu, M. Q. Yan, M. L. Shi, Q. D. Huang, B. Li, W. Y. Wu, R. S. Xia, S. F. Li, S. H. Chen and G. Y. Lv, *Front. Pharmacol.*, 2021, **12**, 755140.
- S. H. Yu, X. Sun, M. K. Kim, M. Akther, J. H. Han, T. Y. Kim, J. Jiang, T. B. Kang and K. H. Lee, *J. Ethnopharmacol.*, 2019, **239**, 111917.
- J. H. Yun, E. S. Hwang and G. H. Kim, *Korean J. Food Sci. Technol.*, 2012, **44**(1), 82–88.



- 5 S. Jiang, M. Y. Wang, Z. C. Jiang, S. Zafar, Q. Xie, Y. P. Yang, Y. Liu, H. W. Yuan, Y. Q. Jian and W. Wang, *Molecules*, 2021, **26**(10), 3038.
- 6 M. S. Cheon, T. Yoon, D. Y. Lee, G. Choi, B. C. Moon, A. Y. Lee, B. K. Choo and H. K. Kim, *J. Ethnopharmacol.*, 2009, **122**(3), 473–477.
- 7 H. J. Zhang, B. H. Wang, X. Wang, C. P. Huang, S. M. Xu, J. L. Wang, T. E. Huang, W. L. Xiao, X. L. Tian, X. Q. Lan, Q. Q. Wang and Y. Xiang, *J. Cachexia Sarcopeni.*, 2023, **15**(1), 173–188.
- 8 B. K. Ghimire, S. H. Kim, C. Y. Yu and I. M. Chung, *Plants*, 2022, **11**(11), 1440.
- 9 L. L. Liu, T. K. Q. Ha, W. Ha, W. K. Oh, J. L. Yang and Y. P. Shi, *J. Nat. Prod.*, 2017, **80**(2), 298–307.
- 10 X. Y. Chen, J. Li, W. M. Cheng, H. Jiang, X. F. Xie and R. Hu, *Am. J. Chin. Med.*, 2008, **36**(04), 695–704.
- 11 T. Zhang, D. R. Wan, Y. Y. Li, S. S. Wang, X. T. Zhou, F. Sefidkon and X. Z. Yang, *Molecules*, 2023, **28**(5), 2022.
- 12 G. M. Xue, X. Q. Li, C. Chen, K. Chen, X. B. Wang, Y. C. Gu, J. G. Luo and L. Y. Kong, *J. Nat. Prod.*, 2018, **81**(2), 378–386.
- 13 J. G. Kim, J. W. Lee, T. P. L. Le, J. S. Han, Y. B. Cho, H. Kwon, D. Lee, M. K. Lee and B. Y. Hwang, *J. Nat. Prod.*, 2021, **84**(3), 562–569.
- 14 A. Reddy, J. Lee, J. Seo, B. H. Kim, E. Chung, S. Ryu, Y. Kim, C. Lee, K. Min and Y. Kim, *Arch. Pharm. Res.*, 2006, **29**(7), 591–597.
- 15 Z. G. Shao, L. Z. Li, Y. Z. Zheng, Q. Gong, C. Q. Ke, S. Yao, H. Y. Zhang, C. P. Tang and Y. Ye, *Fitoterapia*, 2022, **159**, 105199.
- 16 P. Luo, Y. F. Cheng, Z. Y. Yin, C. J. Li, J. Xu and Q. Gu, *J. Nat. Prod.*, 2019, **82**(2), 349–357.
- 17 Q. Gu, Y. Y. Chen, H. Cui, D. Huang, J. W. Zhou, T. Z. Wu, Y. P. Chen, L. N. Shi and J. Xv, *RSC Adv.*, 2013, **3**(26), 10168.
- 18 W. Stöcklin, T. G. Waddell and T. A. Geissman, *Tetrahedron*, 1970, **26**(10), 2397–2409.
- 19 J. Lee, M. Yang, J. Lee, S. Hwang, Y. Kho and K. H. Park, *Planta Med.*, 2003, **69**(9), 880–882.
- 20 N. P. Sahu, S. B. Mahato, S. K. Sarkar and G. Poddar, *Phytochemistry*, 1996, **41**(4), 1181–1185.
- 21 N. D. Abdullaev, M. R. Yagudaev, V. A. Tarasov, Sh. Z. Kasymov and G. P. Sidyakin, *Chem. Nat. Compd.*, 1979, **15**(3), 285–289.
- 22 M. Haruna, M. Kato, K. Ito, T. Nikai, H. Sugihara and H. Muratat, *Phytochemistry*, 1981, **20**(11), 2583–2584.
- 23 H. Heymann, Y. Tezuka, T. Kikuchi and S. Supriyatna, *Chem. Pharm. Bull.*, 1994, **42**(1), 138–146.
- 24 W. Y. Tsui and G. D. Brown, *J. Nat. Prod.*, 1996, **59**(11), 1084–1086.
- 25 Y. Y. Zhang, Y. D. Yao, Q. Q. Cheng, Y. F. Huang and H. Zhou, *Curr. Drug Metab.*, 2022, **23**(5), 394–414.

